JBM  Vol.5 No.8 , August 2017
Notoginsenoside R1 Attenuates Hypoxia and Hypercapnia-Induced Vasoconstriction In Vitro by Reducing the Expression of p38
Abstract: Notoginsenoside R1, the main active ingredient of Panax notoginseng saponins (PNS), has been proposed to play fatal roles in the development of hypoxic hypercapnia-induced pulmonary vasoconstriction (HHPV). Subsequently, pulmonary arterial smooth muscle cells (PASMCs) lead to pulmonary vascular system remodeling and chronic pulmonary disease in the development of HHPV. Despite considerable studies have contributed to pulmonary disease, the mechanism of how Notoginsenoside R1 affects HHPV remains unclear. In this view, we will discuss the effect of notoginsenoside R1 by investigating the expression of p38 mitogen-activated protein kinase (p38 MAPK) signaling pathway in PASMCs under hypoxia and hypercapnia condition. The third order PASMCs of Sprague Dawley (SD) rats were cultured with various concentrations (8, 40, 100 mg/L, respectively) of Notoginsenoside R1. Our data showed that the protein and mRNA expression levels of p-38 MAPK were higher in hypoxic hypercapnia group compared with hypoxic DMSO and normoxia control groups (p < 0.01). In R1 treatment groups, the level of p-p38 MAPK protein and p38 MAPK mRNA were significantly decreased with different degrees (p < 0.01, each). This study provides the evidence that Notoginsenoside R1 treatment may contribute to attenuate HHPV via decreasing the protein and mRNA expression levels of p-38 MAPK.
Cite this paper: Zhang, C. , Zhao, M. , Zheng, M. , Song, L. and Wang, W. (2017) Notoginsenoside R1 Attenuates Hypoxia and Hypercapnia-Induced Vasoconstriction In Vitro by Reducing the Expression of p38. Journal of Biosciences and Medicines, 5, 1-10. doi: 10.4236/jbm.2017.58001.

[1]   Humbert, M. (2009) Update in Pulmonary Hypertension 2008. American Journal of Respiratory and Critical Care Medicine, 179, 650-656.

[2]   Mooi, W.J. and Grungerg K. (2006) Histopathology of Pulmonary Hypertensive Diseases. Current Diagnostic Pathology, 12, 429-440.

[3]   Morrell, N.W., Adnot, S., Archer, S.L., Dupuis, J., Jones, P.L., MacLean, M.R., et al. (2009) Cellular and Molecular Basis of Pulmonary Arterial Hypertension. Journal of the American College of Cardiology, 54, 20-31.

[4]   Pietra, G.G., Capron, F., Stewart, S., Leone, O., Humbert, M., Robbins, I.M., et al. (2004) Pathologic Assessment of Vasculopathies in Pulmonary Hypertension. Journal of the American College of Cardiology, 43, 25S-32S.

[5]   Rajagopalan, N., Simon, M.A., Suffoletto, M.S., Shah, H., Edelman, K., Mathier, M.A., et al. (2009) Noninvasive Estimation of Pulmonary Vascular Resistance in Pulmonary Hypertension. Echocardiography, 26, 489-494.

[6]   Simonneau, G., Gatzoulis, M.A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M.A., Krishna Kumar, R., Landzberg, M., Machado, R.F., Olschewski, H., Robbins, I.M. and Souza, R. (2013) Updated Clinical Classification of Pulmonary Hypertension. Journal of the American College of Cardiology, 62, D34-41.

[7]   McLaughlin, V.V., Archer, S.L., Badesch, D.B., Barst, R.J., Farber, H.W., Lindner, J.R., Mathier, M.A., McGoon, M.D., Park, M.H., Rosenson, R.S., Rubin, L.J., Tapson, V.F., Varga, J., Harrington, R.A., Anderson, J.L., Bates, E.R., Bridges, C.R., Eisenberg, M.J., Ferrari, V.A., Grines, C.L., Hlatky, M.A., Jacobs, A.K., Kaul, S., Lichtenberg, R.C., Moliterno, D.J., Mukherjee, D., Pohost, G.M., Schofield, R.S., Shubrooks, S.J., Stein, J.H., Tracy, C.M., Weitz, H.H. and Wesley, D.J. (2009) ACCF/ AHA 2009 Expert Consensus Document on Pulmonary Hypertension a Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; And the Pulmonary Hypertension Association. Journal of the American College of Cardiology, 119, 2250-2294.

[8]   Michelakis, E.D., Wilkins, M.R. and Rabinovitch, M. (2008) Emerging Concepts and Translational Priorities in Pulmonary Arterial Hypertension. Circulation, 118, 1486-1495.

[9]   Moreno-Vinasco, L., Gomber-Maitland, M., Maitland, M., Desai, A., Singleton, P., Sammani, S., Sam, L., Liu, Y., Husain, A., Lang, R., Ratain, M., Lussier, Y. and Garcia, J. (2008) Genomic Assessment of a Multikinase Inhibitor, Sorafenib, in a Rodent Model of Pulmonary Hypertension. Physiological Genomics, 33, 278-291.

[10]   Macchia, A., Marchioli, R., Tognoni, G., Scarano, M., Marfisi, R., Tavazzi, L. and Rich, S. (2010) Systematic Review of Trials Using Vasodilators in Pulmonary Arterial Hypertension: Why a New Approach is Needed. American Heart Journal, 159, 245-257.

[11]   Ivy, D. and Saji, B.T. (2010) A New Era in Medical Management of Severe Pediatric Pulmonary Arterial Hypertension. Nihon Shoni Junkanki Gakkai Zasshi, 26, 206-218.

[12]   Kumar, R., Mickael, C., Chabon, J., Gebreab, L., Rutebemberwa, A., Garcia, A.R., Koyanagi, D.E., Sanders, L., Gandjeva, A., Kearns, M.T., Barthel, L., Janssen, W.J., Mauad, T., Bandeira, A., Schmidt, E., Tuder, R.M. and Graham, B.B. (2015) The Causal Role of IL-4 and IL-13 in Schistosoma Mansoni Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 192, 998-1008.

[13]   Ng, T.B. (2006) Pharmacological Activity of Sanchi Ginseng (Panax Notoginseng). Journal of Pharmacy and Pharmacology, 58, 1007-1019.

[14]   Nah, S.Y., Park, H.J. and McClesky, E.W. (1995) A Trace Component of Ginseng that Inhibit Ca2+ Channels through a Pertussis Toxin-Sensitive G Protein. Proceedings of the National Academy of Sciences of the United States of America, 92, 8739-8743.

[15]   Xu, Q.H., Fang, X.L. and Chen, D.F. (2003) Pharmacokinetics and Bioavailability of Ginsenoside Rb1 and Rg1 from Panax Notoginseng in Rats. Journal of Ethnopharmacology, 84, 187-192.

[16]   Chen, S.W., Li, X.H., Ye, K.H., Jiang, Z.F. and Ren, X.D. (2004) Total Saponins of Panax Notoginseng Protect Rabbit Iliac Artery against Balloon Endothelial Denudation Injury. Acta Pharmaceutica Sinica, 25, 1151-1156.

[17]   Wang, C.Z., McEntee, E., Wicks, S., Wu, J.A. and Yuan, C.S. (2006) Phytochemical and Analytical Studies of Panax Notoginseng (Burk.). Journal of Natural Medicines, 60, 97-106.

[18]   Ma, W.P., Yang, Y.N., Zhou, D.B. and Zhou, W.Q. (2004) The Preventive Effect of Panax Notoginseng Saponins (PNS) on Chronic Hypoxic Pulmonary Hypertension in Rats. Chinese Journal of Pathophysiology, 20, 1074-1077.

[19]   Mortimer, H.J., Peacock, A.J., Kirk, A. and Welsh, D.J. (2007) P38 MAP Kinase: Essential Role in Hypoxia-Mediated Human Pulmonary Artery Fibroblast Proliferation. Pulmonary Pharmacology & Therapeutics, 20, 718-725.

[20]   Welsh, D.J., Scott, P.H. and Peacock, A.J. (2006) P38 MAP Kinase Isoform Activity and Cell Cycle Regulators in the Proliferative Response of Pulmonary and Systemic Artery Fibroblasts to Acute Hypoxia. Pulmonary Pharmacology & Therapeutics, 19, 128-138.

[21]   Qiu, X., Zheng, M., Song, D., Huang, L., Tang, L., Ying, L. and Wang, W. (2016) Notoginsenoside Rb1 Inhibits Activation of ERK and p38 MAPK Pathways Induced by Hypoxia and Hypercapnia. Experimental and Therapeutic Medicine, 11, 2455-2461.

[22]   Panzhinskiy, E., Zawada, W.M., Stenmark, K.R. and Das, M. (2012) Hypoxia Induces Unique Proliferative Response in Adventitial Fibroblasts by Activating PDGFβ Receptor-JNK1 Signalling. Cardiovascular Research, 95, 356-365.

[23]   Welsh, D., Mortimer, H., Kirk, A. and Peacock, A. (2005) The Role of p38 Mitogen-Activated Protein Kinase in Hypoxia-Induced Vascular Cell Proliferation: An Interspecies Comparison. Chest, 128, 573S-574S.

[24]   Welsh, D.J., Peacock, A.J., MacLean, M. and Harnett, M. (2001) Chronic Hypoxia Induces Constitutive p38 Mitogen-Activated Protein Kinase Activity that Correlates with Enhanced Cellular Proliferation in Fibroblasts from Rat Pulmonary but Not Systemic Arteries. American Journal of Respiratory and Critical Care Medicine, 164, 282-289.

[25]   Goncharova, E.A. (2013) mTOR and Vascular Remodeling in Lung Diseases: Current Challenges and Therapeutic Prospects. The FASEB Journal, 27, 1796-1807.

[26]   Church, A.C., Martin, D.H., Wadsworth, R., Bryson, G., Fisher, A.J., Welsh, D.J. and Peacock, A.J. (2015) The Reversal of Pulmonary Vascular Remodeling through Inhibition of p38 MAPK-Alpha: A Potential Novel Anti-Inflammatory Strategy in Pulmonary Hypertension. American Journal of Physiology-Lung Cellular and Molecular Physiology, 309, L333-347.

[27]   Welch, L.C., Lecuona, E., Briva, A., Trejo, H.E., Dada, L.A. and Sznajdera, J.I. (2010) Extracellular Signal-Regulated Kinase (ERK) Participates in the Hypercapnia-Induced Na, K-ATPase Downregulation. FEBS Letters, 584, 3985-3989.

[28]   Dipp, M. and Evans, A.M. (2001) Cyclic ADP-Ribose Is the Primary Trigger for Hypoxic Pulmonary Vasoconstriction in the Rat Lung in Situ. Circulation Research, 89, 77-83.

[29]   Morio, Y. and McMurtry, I.F. (2002) Ca2+ Release from Ryanodine-Sensitive Store Contributes to Mechanism of Hypoxic Vasoconstriction in Rat Lungs. Journal of Applied Physiology, 92, 527-534.

[30]   Dipp, M., Nye, P.C. and Evans, A.M. (2001) Hypoxic Release of Calcium from the Sarcoplasmic Reticulum of Pulmonary Artery Smooth Muscle. American Journal of Physiology, 281, L318-325.

[31]   Robertson, T.P., Ward, J.P. and Aaronson, P.I. (2001) Hypoxia Induces the Release of a Pulmonary-Selective, Ca2+-Sensitising, Vasoconstrictor from the Perfused Rat Lung. Cardiovascular Research, 50, 145-150.

[32]   Archer, S.L., Huang, J., Henry, T., Peterson, D. and Weir, E.K. (1993) A Redox-Based O2 Sensor in Rat Pulmonary Vasculature. Circulation Research, 73, 1100-1112.

[33]   Firth, A.L., Yuill, K.H. and Smirnov, S.V. (2008) Mitochondria-Dependent Regulation of KV Currents in rat Pulmonary Artery Smooth Muscle Cells. American Journal of Physiology, 295, L61-70.

[34]   Platoshyn, O., Yu, Y., Ko, E.A., Remillard, C.V. and Yuan, J.X. (2007) Heterogeneity of Hypoxia-Mediated Decrease in I(K(V)) and Increase in [Ca2+](cyt) in Pulmonary Artery Smooth Muscle Cells. American Journal of Physiology, 293, L402-416.

[35]   Si, Y.C., Zhang, J.P., Xie, C.E., Zhang, L.J. and Jiang, X.N. (2011) Effects of Panax Notoginseng Saponins on Proliferation and Differentiation of Rat Hippocampal Neural Stem Cells. The American Journal of Chinese Medicine, 39, 999-1013.

[36]   Wang, C.Z., Xie, J.T., Fishbein, A., Aung, H.H., He, H., Mehendale, S.R., He, T.C., Du, W. and Yuan, C.S. (2009) Antiproliferative Effects of Different Plant Parts of Panax Notoginseng on SW480 Human Colorectal Cancer Cells. Phytotherapy Research, 23, 6-13.

[37]   Guo, J., Li, L., Wu, Y.J., Yan, Y., Xu, X.N., Wang, S.B., Yuan, T.Y., Fang, L.H. and Du, G.H. (2013) Inhibitory Effects of Brazilin on the Vascular Smooth Muscle Cell Proliferation and Migration Induced by PDGF-BB. The American Journal of Chinese Medicine, 41, 1283-1296.